Replies to post #21592 on Relief Therapeutics Holding AG (RLFTF)

[Toohie]

Not sure you got my message, was wondering how your group could say that they were not considering to sell any shares till February when the drug might get rejected for approval before that?

[Whalatane]

So how do you prevent PB1046 from entering the market in 3 yrs ?

PB1046
A long-acting VIP analogue for pulmonary arterial hypertension and acute respiratory distress syndrome in patients with COVID-19

Other companies will be developing their own versions .
To date RLFTF has not challenged any other companies synthetic VIP .

RLFTF ...has first mover advantage ..furtherest along in trials for approval. Once approved they get
new indication of an existing drug exclusivity ...thats likely to be it .

Since you claim " your group was 5% of Co ? "...suggest you brush up on patent law and marketing exclusivity .
Above is just my layman understanding of patents / marketing exclusivity ...feel free to correct

In fact it looks as tho these guys are going to try and crash the market with a Sub Q version of our IV RLF-100
https://clinicaltrials.gov/ct2/show/NCT04433546
We may not have marketing exclusivity against sub Q versions ....since we dont have one .....but will defer to your " group " view on this

Kiwi

[arain1234]

How about the long acting subcutaneous VIP formulation by PhaseBio?

[aGuyUS]

Added to Pertinent RLFTF Links Document Here

https://docs.google.com/document/d/1CboxDEE1uR4C0DsgXlsQ_01IfO3o45Oq0Chi712QuP0/edit#heading=h.gt7rg2kdyits